Lipella Pharmaceuticals Inc (LIPO)
0.4906
-0.02
(-3.39%)
USD |
NASDAQ |
Sep 27, 16:00
0.4894
0.00 (0.00%)
After-Hours: 20:00
Lipella Pharmaceuticals Enterprise Value: 2.790M for Sept. 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 27, 2024 | 2.790M |
| September 26, 2024 | 2.929M |
| September 25, 2024 | 2.469M |
| September 24, 2024 | 2.486M |
| September 23, 2024 | 2.142M |
| September 20, 2024 | 2.177M |
| September 19, 2024 | 2.258M |
| September 18, 2024 | 1.976M |
| September 17, 2024 | 2.102M |
| September 16, 2024 | 2.282M |
| September 13, 2024 | 2.088M |
| September 12, 2024 | 1.875M |
| September 11, 2024 | 2.050M |
| September 10, 2024 | 2.116M |
| September 09, 2024 | 2.074M |
| September 06, 2024 | 2.968M |
| September 05, 2024 | 2.096M |
| September 04, 2024 | 2.202M |
| September 03, 2024 | 2.182M |
| August 30, 2024 | 2.217M |
| August 29, 2024 | 2.254M |
| August 28, 2024 | 2.354M |
| August 27, 2024 | 2.554M |
| August 26, 2024 | 2.671M |
| August 23, 2024 | 3.024M |
| Date | Value |
|---|---|
| August 22, 2024 | 2.217M |
| August 21, 2024 | 2.326M |
| August 20, 2024 | 2.267M |
| August 19, 2024 | 2.148M |
| August 16, 2024 | 2.055M |
| August 15, 2024 | 2.171M |
| August 14, 2024 | 2.303M |
| August 13, 2024 | 2.424M |
| August 12, 2024 | 2.549M |
| August 09, 2024 | 2.609M |
| August 08, 2024 | 2.944M |
| August 07, 2024 | 3.368M |
| August 06, 2024 | 3.672M |
| August 05, 2024 | 4.099M |
| August 02, 2024 | 4.658M |
| August 01, 2024 | 5.010M |
| July 31, 2024 | 5.287M |
| July 30, 2024 | 5.633M |
| July 29, 2024 | 5.652M |
| July 26, 2024 | 1.887M |
| July 25, 2024 | 1.818M |
| July 24, 2024 | 2.047M |
| July 23, 2024 | 2.16M |
| July 22, 2024 | 2.201M |
| July 19, 2024 | 2.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.253M
Minimum
Mar 06 2024
27.01M
Maximum
Dec 20 2022
5.674M
Average
4.220M
Median
Enterprise Value Benchmarks
| vTv Therapeutics Inc | -9.62M |
| Ventyx Biosciences Inc | -76.19M |
| CEL-SCI Corp | 66.64M |
| AIM ImmunoTech Inc | 8.574M |
| IGC Pharma Inc | 25.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9381M |
| Total Expenses (Quarterly) | 0.9522M |
| EPS Diluted (Quarterly) | -0.12 |
| Earnings Yield | -122.3% |
| Normalized Earnings Yield | -158.99 |